Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Publication year range
1.
Nat Prod Commun ; 8(10): 1353-4, 2013 Oct.
Article in English | MEDLINE | ID: mdl-24354171

ABSTRACT

The dichloromethane fraction of Ferula ferulaeoides was analyzed by GC and GC-MS, and thirty-four compounds were identified. The main component in the fraction, guaiol (37.0%) was separated by chromatographic methods and identified from spectroscopic data, including 1H and 13C NMR, and X-ray crystallographic diffraction. Guaiol showed significant inhibition of aphids at a concentration of 70 mg/L. It also showed good contact activities against the 4th instar larvae of Mythimna separate and 3rd instar larvae of Plutella xylostella, with LD50 values of 0.07 and 8.9 mg/larva, as well as fumigation activity against the 4th instar larvae ofM. separata and adult Musca domestica, with LC50 values of 3.5 microL/L and 16.9 microL/L, respectively.


Subject(s)
Ferula/chemistry , Insecticides/isolation & purification , Sesquiterpenes/isolation & purification , Animals , Insecta , Sesquiterpenes, Guaiane
2.
Nat Prod Commun ; 7(7): 889-90, 2012 Jul.
Article in English | MEDLINE | ID: mdl-22908573

ABSTRACT

Extract of celery (Apium graveolens L.) seeds was investigated against phytopathogenic fungi. The light petroleum extract showed promising inhibition activities in the tests against Rhizoctonia solani and Fusarium oxysporum f. sp. vasinfecum. Chromatographic separation of the extract gave 19 fractions, one of which, QCZ-4, possessed significant inhibitory rates of 64.6%, 88.4% and 54.7% at a concentration of 100 ppm against R. solani, F. oxysporium f. sp. vasinfecum and Alternaria alternata, respectively. Major components in the active fraction were identified by GC-MS as p-(2-aminoethyl)phenol (39.7%), 3-(3,4-dimethybenzoyl) propionic acid (32.6%) and p-heptylphenol (26.9%).


Subject(s)
Antifungal Agents/chemistry , Antifungal Agents/pharmacology , Apium/chemistry , Seeds/chemistry , Fusarium/drug effects , Gas Chromatography-Mass Spectrometry , Rhizoctonia/drug effects
3.
Zhonghua Gan Zang Bing Za Zhi ; 11(7): 415-7, 2003 Jul.
Article in Chinese | MEDLINE | ID: mdl-12890345

ABSTRACT

OBJECTIVES: To explore whether PreS2 can change the percentage of T lymphocyte subgroups and the ration of CD4+/CD8+ in hepatocellular carcinoma (HCC) caused by HBV. METHODS: The P120-146 region composed by the way of Merrifield, which was the most intensive antigen in PreS2 peptides, served as the antigen after dissolved in 0.01 mol/L PBS. 12 patients were chosed as the subjects, who were pathologically diagnosed as HCC after operation, were HBsAg-, HBeAg-, anti-HBc, and HBV DNA positive in serum, and expressed HBsAg in HCC tissue. The monocytes were isolated and cultured in 96 microplate with 1x 10(6) cells in every well, then the PreS2 synthetic peptides was added in at the doses of 1microg, 5microg, and 10microg, also IL-2 with 500 U was added in. Seven days later, the percentage of CD3+, CD4+, CD8+, and the ratio of CD4+/CD8+ were detected. RESULTS: It was found that the percentage of CD4+ increased significantly (t = 3.508, P < 0.01), and the ratio of CD4+/CD8+ decreasedly obviously (t = 2.235, P < 0.05) in the 5microg PreS2 synthetic peptides group, compared with those in the control group. The percentage of CD3+ rised markedly in the IL-2 group, compared with that in the control group. CONCLUSION: With proper doses, PreS2 is capable of changing the expression of T lymphocyte subgroups in HCC tissue, increasing the percentage of CD4+ obviously and changing the motionless state of CD8+, to make the carcinoma cell killed through the action of CD4+ and CD8+.


Subject(s)
Carcinoma, Hepatocellular/drug therapy , Hepatitis B Surface Antigens/pharmacology , Liver Neoplasms/drug therapy , Lymphocytes, Tumor-Infiltrating/drug effects , Peptide Fragments/pharmacology , Protein Precursors/pharmacology , Amino Acid Sequence , CD4-CD8 Ratio , Carcinoma, Hepatocellular/immunology , Dose-Response Relationship, Drug , Hepatitis B Surface Antigens/therapeutic use , Humans , Liver Neoplasms/immunology , Lymphocytes, Tumor-Infiltrating/immunology , Molecular Sequence Data , Protein Precursors/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...